New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

Russo Alessandro; Lopes Ana Rita; McCusker Michael G.; Garrigues Sandra Gimenez; Ricciardi Giuseppina R.; Arensmeyer Katherine E.; Scilla Katherine A.; Mehra Ranee; Rolfo Christian

首页> 外文期刊>Current oncology reports. >New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

【24h】

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

机译：肺癌新靶标（不包括EGFR，ALK，ROS1）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose of ReviewOver the last two decades, the identification of targetable oncogene drivers has revolutionized the therapeutic landscape of non-small cell lung cancer (NSCLC). The extraordinary progresses made in molecular biology prompted the identification of several rare molecularly defined subgroups. In this review, we will focus on the novel and emerging actionable oncogenic drivers in NSCLC.Recent FindingsRecently, novel oncogene drivers emerged as promising therapeutic targets besides the well-established EGFR mutations, and ALK/ROS1 rearrangements, considerably expanding the list of potential exploitable genetic aberrations. However, the therapeutic algorithm in these patients is far less defined.SummaryThe identification of uncommon oncogene drivers is reshaping the diagnostic and therapeutic approach to NSCLC. The introduction of novel highly selective inhibitors is expanding the use of targeted therapies to rare and ultra-rare subsets of patients, further increasing the therapeutic armamentarium of advanced NSCLC.

机译：None

著录项

来源
《Current oncology reports.》 |2020年第6期|共14页
作者
Russo Alessandro; Lopes Ana Rita; McCusker Michael G.; Garrigues Sandra Gimenez; Ricciardi Giuseppina R.; Arensmeyer Katherine E.; Scilla Katherine A.; Mehra Ranee; Rolfo Christian;
展开▼
作者单位

Univ Maryland Sch Med Marlene &

Stewart Greenebaum Comprehens Canc Ctr 22 S Greene St Rm N9E08;

Univ Maryland Sch Med Marlene &

Stewart Greenebaum Comprehens Canc Ctr 22 S Greene St Rm N9E08;

Univ Maryland Sch Med Marlene &

Stewart Greenebaum Comprehens Canc Ctr 22 S Greene St Rm N9E08;

Univ Maryland Sch Med Marlene &

Stewart Greenebaum Comprehens Canc Ctr 22 S Greene St Rm N9E08;

Univ Messina AO Papardo Med Oncol Unit I-98158 Messina Italy;

Univ Maryland Sch Med Marlene &

Stewart Greenebaum Comprehens Canc Ctr 22 S Greene St Rm N9E08;

Univ Maryland Sch Med Marlene &

Stewart Greenebaum Comprehens Canc Ctr 22 S Greene St Rm N9E08;

Univ Maryland Sch Med Marlene &

Stewart Greenebaum Comprehens Canc Ctr 22 S Greene St Rm N9E08;

Univ Maryland Sch Med Marlene &

Stewart Greenebaum Comprehens Canc Ctr 22 S Greene St Rm N9E08;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
NSCLC; BRAF; MET; NTRK; NRG1; RET; Gene fusion; Rearrangement; Oncogene driver; New targets; Larotrectinib; Entrectinib; LOXO-292; BLU-667; Selpercatinib; Pralsetinib; Afatinib; T-DM1; Pyrotinib; Poziotinib; Tepotinib; Capmatinib;

机译：Capmatinib.;

相似文献

外文文献
中文文献
专利

1. Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer：trials and treatment options [J] . Arpita, Desai, Smitha, 癌症生物学与医学：英文版 . 2016,第001期
2. Alterations in genes other thanEGFR/ALK/ROS1 in non-small cell lung cancer：trials and treatment options [J] . Arpita Desai, Smitha P Menon, Grace K Dy 癌症生物学与医学（英文版） . 2016,第001期
3. ROS1 in Squamous Non-Small Cell Lung Cancer—Combined Immunotherapy (PD1/CTLA4) or Targeted Therapy? [J] . Alexander Yakobson, Tal Mor, Levitas Dina, 癌症治疗（英文） . 2020,第006期
4. Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer:EGFR and beyond [J] . Christopher Delaney, Samuel Frank, R Stephanie Huang 癌症（英文版） . 2015,第004期
5. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy [J] . Bao Ming QIN, Xiao CHEN, Jing De ZHU, 细胞研究（英文版） . 2005,第003期
6. PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1 [J] . Jongmin Lee, Chan Kwon Park, Hyoung‐Kyu Yoon, Thoracic cancer. . 2019,第1期

机译：ROS1重排的非小细胞肺癌中PD-1L1的表达：一项同时进行EGFR，ALK和ROS1基因型筛查的研究
7. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance [J] . Zhang Quan, Sun Tianyu, Kang Poming, Cancer chemotherapy and pharmacology. . 2016,第3期

机译：非小细胞肺癌患者ALK，ROS1重排，EGFR，KRAS，BRAF，PIK3CA体细胞突变以及ERCC1，TYMS，RRM1，TUBB3，EGFR mRNA表达的联合分析及其临床意义
8. Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or BRAF [J] . Xibin Zhuang, Chao Zhao, Jiayu Li, Cancer Medicine . 2019,第6期

机译：伴有EGFR，ALK，ROS1，KRAS或BRAF突变的非小细胞肺癌患者的临床特征和治疗选择
9. Development of EGFR-Targeting Nanomedicine for Effectively and Noninvasively Treats Lung Cancer Patients by Aerosol Delivery [C] . Ching-Li Tseng, Yueh-Hsiu Wu, Su-Wen Yu, World congress on medical physics and biomedical engineering;International congress of the IUPESM . 2011

机译：EGFR靶向纳米药物的开发，可通过气雾剂有效无创地治疗肺癌患者
10. Localization-based Signaling Pathway Dependence of ROS1 Fusions and a Novel Role for Ras in EML4-ALK-Driven Lung Cancer [D] . Neel, Dana Sarabeth. 2017

机译：ROS1融合的基于本地化的信号通路依赖性和在EML4-ALK驱动的肺癌中Ras的新作用。
11. PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR ALK and ROS1 [O] . Jongmin Lee, Chan Kwon Park, Hyoung‐Kyu Yoon, 2019

机译：ROS1重排的非小细胞肺癌中PD-1L1的表达：一项同时进行EGFRALK和ROS1基因型筛查的研究
12. EGFR mutations and ROS1 and ALK rearrangements in a large series of non‐small cell lung cancer in South India [O] . Anil Tarigopula, Gayathri Ramasubban, Vani Chandrashekar, 2020

机译：EGFR突变和ROS1和ALK重排在南印度南部的大系列非小细胞肺癌中
13. Deficient BIM Expression as a Mechanism of Intrinsic and Acquired Resistance to Targeted Therapies in EGFR Mutant and ALK Positive Lung Cancers. [R] . Sequist, L., Engelman, J. 2016

机译：缺乏BIm表达作为EGFR突变体和aLK阳性肺癌中靶向治疗的内在和获得性抗性的机制。

New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1)

摘要

著录项

相似文献

相关主题

期刊订阅